In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization

D. Avtanski; Y. Hirth; N. Babushkin; V. Sy; D. Sharma; L. Poretsky; D. Seto-Young

doi:10.1055/s-0042-101027

In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization

D. Avtanski, Y. Hirth, N. Babushkin, V. Sy, D. Sharma, L. Poretsky, D. Seto-Young

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Pioglitazone is an insulin-sensitizing thiazolidinedione (TZD) whose use is associated with bone loss. We examined the effects of pioglitazone on components of the Wnt signaling pathway (Wnt1, β-catenin) and markers of bone mineralization [osteoprotegerin (OPG), bone sialoprotein (BSP), fibroblast growth factor (FGF)23] as well as mineral content in human osteoblast hFOB 1.19 cells. hFOB 1.19 cells were cultured in K12/DMD medium with or without pioglitazone. PPARγ Wnt1, OPG, BSP, or FGF23 mRNA expression was measured using qRT-PCR; β-catenin, OPG, BSP, or FGF23 using ELISA; and calcium or phosphate content using colorimetry. Treatment with pioglitazone resulted in increased expression of PPARγ mRNA in hFOB 1.19 osteoblasts. Pioglitazone decreased Wnt1 mRNA levels and suppressed components of Wnt signaling pathway as evidenced by a decrease in β-catenin gene expression and secretion as well as β-catenin specific activity. The expression and the activity of OPG, BSP, and FGF23 were also reduced by pioglitazone together with total (but not specific) calcium and phosphate content. Pioglitazone affects Wnt1 signaling pathway and mineral matrix regulation components in human osteoblasts.

Original language	English
Pages (from-to)	468-475
Number of pages	8
Journal	Hormone and Metabolic Research
Volume	48
Issue number	7
DOIs	https://doi.org/10.1055/s-0042-101027
State	Published - 1 Jul 2016
Externally published	Yes

Keywords

BSP
FGF23
OPG
PPARγ
calcium
phosphate
β-catenin

Access to Document

10.1055/s-0042-101027

Cite this

@article{4dde8599854d4458ad1ddb478b420947,

title = "In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization",

abstract = "Pioglitazone is an insulin-sensitizing thiazolidinedione (TZD) whose use is associated with bone loss. We examined the effects of pioglitazone on components of the Wnt signaling pathway (Wnt1, β-catenin) and markers of bone mineralization [osteoprotegerin (OPG), bone sialoprotein (BSP), fibroblast growth factor (FGF)23] as well as mineral content in human osteoblast hFOB 1.19 cells. hFOB 1.19 cells were cultured in K12/DMD medium with or without pioglitazone. PPARγ Wnt1, OPG, BSP, or FGF23 mRNA expression was measured using qRT-PCR; β-catenin, OPG, BSP, or FGF23 using ELISA; and calcium or phosphate content using colorimetry. Treatment with pioglitazone resulted in increased expression of PPARγ mRNA in hFOB 1.19 osteoblasts. Pioglitazone decreased Wnt1 mRNA levels and suppressed components of Wnt signaling pathway as evidenced by a decrease in β-catenin gene expression and secretion as well as β-catenin specific activity. The expression and the activity of OPG, BSP, and FGF23 were also reduced by pioglitazone together with total (but not specific) calcium and phosphate content. Pioglitazone affects Wnt1 signaling pathway and mineral matrix regulation components in human osteoblasts.",

keywords = "BSP, FGF23, OPG, PPARγ, calcium, phosphate, β-catenin",

author = "D. Avtanski and Y. Hirth and N. Babushkin and V. Sy and D. Sharma and L. Poretsky and D. Seto-Young",

note = "Publisher Copyright: {\textcopyright} Georg Thieme Verlag Stuttgart - New York.",

year = "2016",

month = jul,

day = "1",

doi = "10.1055/s-0042-101027",

language = "English",

volume = "48",

pages = "468--475",

journal = "Hormone and Metabolic Research",

issn = "0018-5043",

publisher = "Georg Thieme Verlag",

number = "7",

}

TY - JOUR

T1 - In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization

AU - Avtanski, D.

AU - Hirth, Y.

AU - Babushkin, N.

AU - Sy, V.

AU - Sharma, D.

AU - Poretsky, L.

AU - Seto-Young, D.

N1 - Publisher Copyright: © Georg Thieme Verlag Stuttgart - New York.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Pioglitazone is an insulin-sensitizing thiazolidinedione (TZD) whose use is associated with bone loss. We examined the effects of pioglitazone on components of the Wnt signaling pathway (Wnt1, β-catenin) and markers of bone mineralization [osteoprotegerin (OPG), bone sialoprotein (BSP), fibroblast growth factor (FGF)23] as well as mineral content in human osteoblast hFOB 1.19 cells. hFOB 1.19 cells were cultured in K12/DMD medium with or without pioglitazone. PPARγ Wnt1, OPG, BSP, or FGF23 mRNA expression was measured using qRT-PCR; β-catenin, OPG, BSP, or FGF23 using ELISA; and calcium or phosphate content using colorimetry. Treatment with pioglitazone resulted in increased expression of PPARγ mRNA in hFOB 1.19 osteoblasts. Pioglitazone decreased Wnt1 mRNA levels and suppressed components of Wnt signaling pathway as evidenced by a decrease in β-catenin gene expression and secretion as well as β-catenin specific activity. The expression and the activity of OPG, BSP, and FGF23 were also reduced by pioglitazone together with total (but not specific) calcium and phosphate content. Pioglitazone affects Wnt1 signaling pathway and mineral matrix regulation components in human osteoblasts.

AB - Pioglitazone is an insulin-sensitizing thiazolidinedione (TZD) whose use is associated with bone loss. We examined the effects of pioglitazone on components of the Wnt signaling pathway (Wnt1, β-catenin) and markers of bone mineralization [osteoprotegerin (OPG), bone sialoprotein (BSP), fibroblast growth factor (FGF)23] as well as mineral content in human osteoblast hFOB 1.19 cells. hFOB 1.19 cells were cultured in K12/DMD medium with or without pioglitazone. PPARγ Wnt1, OPG, BSP, or FGF23 mRNA expression was measured using qRT-PCR; β-catenin, OPG, BSP, or FGF23 using ELISA; and calcium or phosphate content using colorimetry. Treatment with pioglitazone resulted in increased expression of PPARγ mRNA in hFOB 1.19 osteoblasts. Pioglitazone decreased Wnt1 mRNA levels and suppressed components of Wnt signaling pathway as evidenced by a decrease in β-catenin gene expression and secretion as well as β-catenin specific activity. The expression and the activity of OPG, BSP, and FGF23 were also reduced by pioglitazone together with total (but not specific) calcium and phosphate content. Pioglitazone affects Wnt1 signaling pathway and mineral matrix regulation components in human osteoblasts.

KW - BSP

KW - FGF23

KW - OPG

KW - PPARγ

KW - calcium

KW - phosphate

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84957711202&partnerID=8YFLogxK

U2 - 10.1055/s-0042-101027

DO - 10.1055/s-0042-101027

M3 - Article

C2 - 26849824

AN - SCOPUS:84957711202

SN - 0018-5043

VL - 48

SP - 468

EP - 475

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

IS - 7

ER -

In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization

Abstract

Keywords

Access to Document

Fingerprint

Cite this